Ipsen S.A. publishes its 2023 Consolidated Financial Statements

- 15 February 2024 - 1 mins read

Ipsen S.A. – 2023 Consolidated Financial Statements

Attachment

Related stories
14 October 2024 1 mins read

Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
29 June 2022 1 mins read

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
01 June 2021 1 mins read

Ipsen announces the launch of an Employee Shareholding Plan
See more stories

Related Press Releases

13 July 2026

IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients...
09 July 2026

Dysport® is the first botulinum toxin to achieve positive topline...
01 July 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus...
29 June 2026

Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
28 May 2026

New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and...
19 May 2026

Ipsen announces late-breaking data from first head-to-head study comparing Dysport®...
16 May 2026

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar...
14 May 2026

Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the...
23 April 2026

Ipsen delivers strong sales in the first quarter of 2026...
22 April 2026

Ojemda® approved in the European Union as the first targeted...